苯达莫司汀时代对转化型惰性淋巴瘤自体干细胞移植的重新评估。 - Suppr

Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era.

作者信息

Stewart Colin, Owen Carolyn, Shafey Mona, Perry Sarah, Sterrett Russell, Peters Anthea, Duggan Peter, Chua Neil, Stewart Douglas, Puckrin Robert

机构信息

Alberta Health Services and University of Calgary, Calgary, AB, Canada.

Alberta Health Services and University of Alberta, Edmonton, AB, Canada.

出版信息

Bone Marrow Transplant. 2024 Nov;59(11):1618-1620. doi: 10.1038/s41409-024-02399-9. Epub 2024 Aug 20.

DOI:10.1038/s41409-024-02399-9

PMID:39164483

Abstract

摘要

相似文献

Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era.苯达莫司汀时代对转化型惰性淋巴瘤自体干细胞移植的重新评估。

Bone Marrow Transplant. 2024 Nov;59(11):1618-1620. doi: 10.1038/s41409-024-02399-9. Epub 2024 Aug 20.

Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?在化疗免疫治疗时代重新评估惰性 B 细胞淋巴瘤的自体移植作用：它是否仍然相关？

Bone Marrow Transplant. 2013 Aug;48(8):1013-21. doi: 10.1038/bmt.2012.182. Epub 2012 Sep 24.

Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation.未经自体干细胞移植和经自体干细胞移植治疗的惰性转化淋巴瘤的转归决定因素。

Ann Oncol. 2015 Feb;26(2):393-9. doi: 10.1093/annonc/mdu537. Epub 2014 Nov 18.

Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.转化型非滤泡性惰性淋巴瘤患者接受异基因和自体干细胞移植后的良好预后。

Biol Blood Marrow Transplant. 2014 Nov;20(11):1813-8. doi: 10.1016/j.bbmt.2014.07.015. Epub 2014 Jul 18.

The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.苯达莫司汀的发现和发展用于治疗非霍奇金淋巴瘤。

Expert Opin Drug Discov. 2016 Nov;11(11):1123-1130. doi: 10.1080/17460441.2016.1233174. Epub 2016 Sep 16.

Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.苯达莫司汀用于治疗惰性B细胞淋巴瘤患者，包括慢性淋巴细胞白血病。

Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009045. doi: 10.1002/14651858.CD009045.pub2.

Bendamustine: role and evidence in lymphoma therapy, an overview.苯达莫司汀：淋巴瘤治疗中的作用与证据概述

Leuk Lymphoma. 2014 Jul;55(7):1471-8. doi: 10.3109/10428194.2013.842986. Epub 2014 Feb 4.

Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.自体干细胞移植治疗初治转化惰性 B 细胞淋巴瘤：一项国际多中心倾向评分匹配研究。

Br J Haematol. 2020 Dec;191(5):806-815. doi: 10.1111/bjh.17072. Epub 2020 Oct 16.

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.利妥昔单抗时代，自体干细胞移植高剂量化疗用于转化型B细胞非霍奇金淋巴瘤患者

Leuk Lymphoma. 2014 Oct;55(10):2319-27. doi: 10.3109/10428194.2013.871632. Epub 2014 Mar 19.

Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study.剂量调整的苯达莫司汀替代卡莫司汀在自体干细胞移植治疗复发淋巴瘤患者中的预处理：一项回顾性单中心研究。

Hematol Oncol Stem Cell Ther. 2021 Dec;14(4):327-335. doi: 10.1016/j.hemonc.2020.11.003. Epub 2020 Nov 24.

引用本文的文献

Clinical characteristics of duodenal-type follicular lymphoma.十二指肠型滤泡性淋巴瘤的临床特征

Discov Oncol. 2025 Jul 8;16(1):1280. doi: 10.1007/s12672-025-02482-7.

本文引用的文献

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.惰性淋巴瘤的共存对新诊断弥漫性大 B 细胞淋巴瘤临床结局的影响。

Blood. 2019 Oct 17;134(16):1289-1297. doi: 10.1182/blood.2019000858.

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.苯达莫司汀-利妥昔单抗治疗后早期进展与晚期滤泡性淋巴瘤转化风险高相关。

Blood. 2019 Aug 29;134(9):761-764. doi: 10.1182/blood.2019000258. Epub 2019 Jul 12.

Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.利妥昔单抗时代的转化滤泡性淋巴瘤：来自西班牙淋巴瘤肿瘤学组的报告。

Hematol Oncol. 2019 Apr;37(2):143-150. doi: 10.1002/hon.2601. Epub 2019 Apr 4.

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.利妥昔单抗与滤泡性淋巴瘤转化风险：一项回顾性汇总分析

Lancet Haematol. 2018 Aug;5(8):e359-e367. doi: 10.1016/S2352-3026(18)30090-5. Epub 2018 Jul 4.

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.挽救性化疗和自体干细胞移植治疗转化惰性淋巴瘤：NCIC CTG LY12 的亚组分析。

Blood. 2015 Aug 6;126(6):733-8. doi: 10.1182/blood-2015-01-622084. Epub 2015 Jun 24.

Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.利妥昔单抗时代的转化型非霍奇金淋巴瘤：NCCN 结局数据库分析。

Br J Haematol. 2013 Nov;163(4):487-95. doi: 10.1111/bjh.12570. Epub 2013 Sep 20.

Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.免疫化疗时代滤泡性淋巴瘤转化的发生率和结局：来自爱荷华大学/梅奥诊所卓越研究计划分子流行病学资源的报告。

J Clin Oncol. 2013 Sep 10;31(26):3272-8. doi: 10.1200/JCO.2012.48.3990. Epub 2013 Jul 29.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.苯达莫司汀联合利妥昔单抗与 CHOP 联合利妥昔单抗作为惰性和套细胞淋巴瘤患者一线治疗的比较：一项开放标签、多中心、随机、3 期非劣效性临床试验。

Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20.

Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.自体和同种异体干细胞移植治疗转化滤泡性淋巴瘤：加拿大血液和骨髓移植组的报告。

J Clin Oncol. 2013 Mar 20;31(9):1164-71. doi: 10.1200/JCO.2012.44.0693. Epub 2013 Feb 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献